DE69927286D1 - Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs - Google Patents

Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs

Info

Publication number
DE69927286D1
DE69927286D1 DE69927286T DE69927286T DE69927286D1 DE 69927286 D1 DE69927286 D1 DE 69927286D1 DE 69927286 T DE69927286 T DE 69927286T DE 69927286 T DE69927286 T DE 69927286T DE 69927286 D1 DE69927286 D1 DE 69927286D1
Authority
DE
Germany
Prior art keywords
treatment
cell lines
cancer
prostate
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927286T
Other languages
English (en)
Other versions
DE69927286T2 (de
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyvax Ltd
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Publication of DE69927286D1 publication Critical patent/DE69927286D1/de
Application granted granted Critical
Publication of DE69927286T2 publication Critical patent/DE69927286T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/884Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69927286T 1998-12-10 1999-12-09 Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs Expired - Lifetime DE69927286T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9827104 1998-12-10
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004129 WO2000033869A2 (en) 1998-12-10 1999-12-09 Use of human prostrate cell lines in cancer treatment

Publications (2)

Publication Number Publication Date
DE69927286D1 true DE69927286D1 (de) 2005-10-20
DE69927286T2 DE69927286T2 (de) 2006-06-29

Family

ID=10843926

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927286T Expired - Lifetime DE69927286T2 (de) 1998-12-10 1999-12-09 Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs

Country Status (19)

Country Link
US (3) US6972128B1 (de)
EP (1) EP1137422B1 (de)
JP (2) JP4949554B2 (de)
KR (1) KR20010090874A (de)
AT (1) ATE304365T1 (de)
AU (1) AU763485B2 (de)
CA (1) CA2354045C (de)
CZ (1) CZ300499B6 (de)
DE (1) DE69927286T2 (de)
ES (1) ES2249046T3 (de)
GB (1) GB9827104D0 (de)
HU (1) HUP0104568A3 (de)
IL (2) IL143296A0 (de)
MX (1) MXPA01005816A (de)
NO (1) NO327044B1 (de)
NZ (1) NZ512004A (de)
PL (1) PL201016B1 (de)
WO (1) WO2000033869A2 (de)
ZA (1) ZA200104164B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
AU4935700A (en) * 1999-05-21 2000-12-12 Onyvax Limited New vaccine formulations-3
WO2001075073A2 (en) * 2000-04-01 2001-10-11 Onyvax Limited Prostate cell lines and their use
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
JP2007503435A (ja) * 2003-08-26 2007-02-22 ベクトン・ディキンソン・アンド・カンパニー 治療薬の皮内送達法
KR101323540B1 (ko) 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性t細胞の誘導方法、細胞傷害性t細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
EP2376089B1 (de) * 2008-11-17 2018-03-14 The Regents of the University of Michigan Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
AU2370195A (en) * 1994-04-28 1995-11-29 Scott Freeman Cell lines obtained by (in vivo) migration and by fusion with autoimmune cells
US5837233A (en) * 1995-03-17 1998-11-17 University Of California Method for treating tumors
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ATE237338T1 (de) * 1995-12-28 2003-05-15 Univ Johns Hopkins Med Allogene parakrine cytokine tumor impfstoffe
US6982168B1 (en) * 1996-02-02 2006-01-03 The United States Of America As Represented By The Department Of Health And Human Services Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
EP1137422A2 (de) 2001-10-04
GB9827104D0 (en) 1999-02-03
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24
IL143296A (en) 2006-06-11
NO20012634L (no) 2001-08-08
NZ512004A (en) 2003-08-29
ES2249046T3 (es) 2006-03-16
CZ20012032A3 (cs) 2001-10-17
MXPA01005816A (es) 2002-03-27
US20120164099A1 (en) 2012-06-28
IL143296A0 (en) 2002-04-21
KR20010090874A (ko) 2001-10-19
JP2002531520A (ja) 2002-09-24
WO2000033869A2 (en) 2000-06-15
NO20012634D0 (no) 2001-05-29
EP1137422B1 (de) 2005-09-14
CZ300499B6 (cs) 2009-06-03
PL348828A1 (en) 2002-06-17
CA2354045C (en) 2012-02-21
JP2012021028A (ja) 2012-02-02
AU763485B2 (en) 2003-07-24
AU1668300A (en) 2000-06-26
JP4949554B2 (ja) 2012-06-13
DE69927286T2 (de) 2006-06-29
NO327044B1 (no) 2009-04-06
ATE304365T1 (de) 2005-09-15
US20050249756A1 (en) 2005-11-10
WO2000033869A3 (en) 2000-10-12
HUP0104568A3 (en) 2004-05-28
US6972128B1 (en) 2005-12-06
HUP0104568A2 (hu) 2002-03-28
PL201016B1 (pl) 2009-02-27
CA2354045A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
NO20021830D0 (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
TR200102308T2 (tr) Yüzey etkinliğine sahip yapay peptidler ve bunların yapay yüzey aktif maddelerin hazırlanmasında kullanımı
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69927286D1 (de) Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs
AU4559300A (en) Use of phyllanthus for targeted stimulation of the immune system
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
DE69723580D1 (de) Impfstoff gegen metastasierenden kolorektalkrebs.
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
TR200200278T2 (tr) Kalsilitik bileşimler
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE541566T1 (de) Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche
NO20005548D0 (no) Mykobakterieinhibitorer
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
ATE306929T1 (de) Inositolphosphoglycan und ribose zur behandlung von ischämischen-reperfusionschaden
DE60230641D1 (de) Lentivirale vektoren zur behandlung von schmerzen
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition